Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective multicenter study of risk factors for cetuximab-related infusion reactions in Japanese patients
jRCT1040210116Completed
- Sponsor
- Yaizu City Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab in colorectal cancer (CRC) and head and neck cancer (HNC), sponsored by Yaizu City Hospital. Primary endpoint: Exploratory factor analysis of risk of cetuximab-related infusion reaction. Started Jan 2022; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT1040210116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040210116.